Stereotactic Radiotherapy Management of Brain Metastases: the Value of a Longitudinal Multimodal Approach (POSTPONE)

Launched by UNIVERSITY HOSPITAL, BREST · Sep 6, 2023

Keywords

ClinConnect Summary

The POSTPONE trial is studying how to better manage brain metastases, which are cancer cells that have spread to the brain from other parts of the body. This trial is important because a significant number of cancer patients—between 20% and 40%—will develop these brain metastases. Traditionally, whole-brain radiotherapy was the main treatment, but recent studies show that a more precise method called stereotactic radiotherapy (SR) is now preferred. The trial aims to explore different ways to monitor patients after they receive SR, focusing on how early imaging can help predict survival and how to diagnose any complications that may arise.

To be eligible for this trial, participants must be at least 18 years old and have a solid cancer that has spread to the brain, treated with stereotactic radiotherapy at a specific hospital. The trial is currently recruiting participants of all genders. Those who join can expect to undergo imaging tests to assess their condition and receive monitoring tools to help manage their treatment over time. This research is designed to improve care for patients with brain metastases and could lead to better outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Patients with solid cancer with brain metastases treated by hypofractionated external stereotactic radiotherapy at the CHRU de Brest between 01/01/2014 and 31/12/2022
• • Patient affiliated to a social security scheme
• Exclusion Criteria:
• • Patients with primary brain tumors
• • Patients treated with normofractionated external cerebral radiotherapy
• • Age \< 18 years
• • Patients under legal protection (guardianship, curatorship, etc.)